Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.20.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Operating Activities:      
Net loss $ (16,395) $ (12,687) $ (10,583)
Adjustments to reconcile net loss to net cash used in operating activities:      
Gain on warrants [note 7 and note 11[e]]     (150)
Depreciation 31 60 59
Amortization 223 222 223
Stock-based compensation [note 11[c]] 1,201 854 348
Cumulative adjustment on adoption of lease standard (3)    
Deferred income tax (recovery) [note 2 and 5]     (3,051)
Bargain purchase gain [note 2]     (1,272)
Loss on disposition [note 2]     8,610
Contingent value rights recovery [note 2]     (200)
Changes in operating assets and liabilities:      
Amounts receivable (1) 2 (9)
Prepaid expenses and other assets 195 (343) (1,349)
Accounts payable 715 (69) 118
Accrued liabilities other (328) 310 (2,185)
Accrued clinical liabilities (812) 322 877
Accrued compensation (52) 710 458
Salaries payable     (1,028)
Lease obligation 10 (4) 27
Net cash used in operating activities (15,216) (10,623) (9,107)
Financing Activities:      
Proceeds from share subscription     64
Proceeds from exercise of warrants, net of issuance costs 4,199 1,324  
Taxes paid related to net share settlement of equity awards     (5)
Net cash provided by financing activities 17,325 19,757 2,001
Investing Activities:      
Cash received on reverse takeover of OncoGenex     12,648
Purchase of property and equipment (53) (46)  
Proceeds on disposal of assets   10  
Purchase of investments (25) (5,539)  
Maturities of investments 5,114 450  
Net cash provided by (used in) investing activities 5,036 (5,125) 12,648
Effect of exchange rate changes on cash 4   (1)
Net increase (decrease) in cash, cash equivalents and restricted cash 7,149 4,009 5,541
Cash, cash equivalents and restricted cash at beginning of year 9,565 5,556 15
Cash, cash equivalents and restricted cash at end of year 16,714 9,565 5,556
LPC [Member]      
Financing Activities:      
Proceeds from purchase agreement and registered direct offering, net of issuance costs 792 1,279 $ 1,942
June 2018 Public Offering [Member]      
Financing Activities:      
Proceeds from public offering, net of issuance costs   12,194  
October 2018 Registered Direct Offering [Member]      
Financing Activities:      
Proceeds from purchase agreement and registered direct offering, net of issuance costs   $ 4,960  
December 2019 Public Offering [Member]      
Financing Activities:      
Proceeds from public offering, net of issuance costs $ 12,334